Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis

Imagem de Miniatura
Arquivos
art_ALVES JUNIOR_Mepolizumab_in_Hypereosinophilic_Syndrome_A_Systematic_Review_and_2021.PDF (1.2 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2021
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
ALVES JUNIOR, Jose Mario
PROTA, Francisco Eduardo
VILLAGELIN, Danilo
BLEY, Fernanda
Citação
CLINICS, v.76, article ID e3271, 7p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
We aimed to evaluate the efficacy and safety of mepolizumab (MEP) in the management of hypereosinophilic syndrome (HES). A systematic search was performed, and articles published until March 2021 were analyzed. The primary efficacy results evaluated were hospitalization rate related to HES, morbidity (new or worsening), relapses/failure, treatment-related adverse effects, prednisone dosage 510 mg/day for ,8 weeks, and eosinophil count <600/mu L for ,8 weeks. A meta-analysis was conducted, when appropriate. Three randomized controlled trials (RCTs), with a total of 255 patients, were included. The studies contemplated the use of MEP 300 mg/SC or 750 mg/IV. According to the evaluation of the proposed outcomes, when relapse rates/therapeutic failures were assessed, there was a 26% reduction with MEP 300 mg/SC (RD=-0.26; 95% CI: -0.44 to -0.08; p=0.04) and 48% reduction with MEP 750 mg/IV (RD=-0.48; 95% CI: -0.67, -0.30; p<0.00001). For the outcomes, prednisone dosage 510 mg/day for ,8 weeks was 48% (RD=0.48; 95% CI: 0.35 to 0.62; p<0.00001), and the eosinophil count <600/mu L for ,8 weeks was 51% (RD=0.51; 95% CI: 0.38 to 0.63; p<0.00001), both showed a reduction with MEP 300 mg/IV and 750 mg/IV. No statistically significant differences in treatment-related adverse effects outcomes were observed for either dosage (RD=0.09; 95% CI: -0.05 to 0.24; p=0.20; RD=0.09; 95% CI: -0.11 to 0.29; p=0.39). Despite the positive effects observed for the studied outcomes, the exact significance remains unclear.
Palavras-chave
Mepolizumab, Humanized Monoclonal Antibody, Hypereosinophilic Syndrome
URI
https://observatorio.fm.usp.br/handle/OPI/44233
Referências
  1. Agache I, 2020, ALLERGY, V75, P1023, DOI 10.1111/all.14221
  2. Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291
  3. Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC
  4. Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X
  5. Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991
  6. Li Kuang F, 2018, J ALLER CL IMM-PRACT, V6, P1518, DOI 10.1016/j.jaip.2018.04.033
  7. Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435
  8. Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290
  9. Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X
  10. Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812
  11. Roufosse F, 2020, J ALLERGY CLIN IMMUN, V146, P1397, DOI 10.1016/j.jaci.2020.08.037
  12. Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P828, DOI 10.1016/j.jaci.2010.06.049
  13. Shomali W, 2019, AM J HEMATOL, V94, P1149, DOI 10.1002/ajh.25617
  14. Stella S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020486
  15. Valent P, 2012, J ALLERGY CLIN IMMUN, V130, P607, DOI 10.1016/j.jaci.2012.02.019
  16. Yancey SW, 2017, J ALLERGY CLIN IMMUN, V139, P1167, DOI 10.1016/j.jaci.2016.08.008

Coleções
Artigos e Materiais de Revistas Científicas - HC/Outros
Artigos e Materiais de Revistas Científicas - LIM/47